Madrigal has set a list price of the Rezdiffra of $47,400 per year, ahead of any discounts or rebates, which lies within the $39,600 to $50,100 range that the influential Institute for Clinical ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

Camilo Fonseca is an express reporter at the Globe. Previously, he worked on the Globe's business desk, covering healthcare and workforce issues. He has also worked at The Seattle Times, where he ...

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers ...